ProPhase Labs Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ProPhase Labs stock.
View analyst ratings for ProPhase Labs or view top-rated stocks.

2 analysts have issued 1-year price objectives for ProPhase Labs' shares. Their PRPH stock forecasts range from $14.00 to $14.00. On average, they predict ProPhase Labs' share price to reach $14.00 in the next year. This suggests a possible upside of 19.4% from the stock's current price.
View analysts' price targets for ProPhase Labs or view top-rated stocks among Wall Street analysts.

ProPhase Labs' stock was trading at $7.17 at the beginning of 2022. Since then, PRPH shares have increased by 63.6% and is now trading at $11.73.
View the best growth stocks for 2022 here.

ProPhase Labs is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for ProPhase Labs.

ProPhase Labs, Inc. (NASDAQ:PRPH) posted its quarterly earnings data on Friday, May, 13th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.29. The business had revenue of $47.53 million for the quarter, compared to analysts' expectations of $24.31 million. ProPhase Labs had a net margin of 15.91% and a trailing twelve-month return on equity of 25.26%.
View ProPhase Labs' earnings history.

ProPhase Labs declared a dividend on Friday, May 13th. Shareholders of record on Wednesday, May 25th will be given a dividend of $0.30 per share on Friday, June 3rd. The ex-dividend date is Tuesday, May 24th.
View ProPhase Labs' dividend history.

2 employees have rated ProPhase Labs CEO Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among ProPhase Labs' employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to ProPhase Labs include Erasca (ERAS), CinCor Pharma (CINC), Evolus (EOLS), Kiniksa Pharmaceuticals (KNSA), Avidity Biosciences (RNA), Northwest Biotherapeutics (NWBO), Keros Therapeutics (KROS), Catalyst Pharmaceuticals (CPRX), Theravance Biopharma (TBPH), Ventyx Biosciences (VTYX), MorphoSys (MOR), Emisphere Technologies (EMIS), Pharvaris (PHVS), POINT Biopharma Global (PNT) and Nuvalent (NUVL).
View all of PRPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Fulcrum Therapeutics (FULC), Novus Therapeutics (NVUS), Onconova Therapeutics (ONTX) and Recro Pharma (REPH).

ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."

ProPhase Labs' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.31%), Renaissance Technologies LLC (1.44%), Avidian Wealth Solutions LLC (0.91%), Bank of New York Mellon Corp (0.28%), State Street Corp (0.20%) and Group One Trading L.P. (0.03%). Company insiders that own ProPhase Labs stock include Jason Michael Barr, Louis Md Gleckel and Ted William Karkus.
View institutional ownership trends for ProPhase Labs.

PRPH stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Group One Trading L.P., and Simplex Trading LLC.
View insider buying and selling activity for ProPhase Labs or view top insider-selling stocks.

PRPH stock was purchased by a variety of institutional investors in the last quarter, including Avidian Wealth Solutions LLC, Vanguard Group Inc., and State Street Corp.
View insider buying and selling activity for ProPhase Labs or or view top insider-buying stocks.

Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRPH stock can currently be purchased for approximately $11.73.

ProPhase Labs (NASDAQ:PRPH) has a market capitalization of $181.65 million and generates $79.04 million in revenue each year. The company earns $6.27 million in net income (profit) each year or $1.009990 on an earnings per share basis.

ProPhase Labs employs 95 workers across the globe.

ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The official website for ProPhase Labs is www.prophaselabs.com. The company can be reached via phone at (215) 345-0919, via email at [email protected], or via fax at 215-345-5920.